Pharmacy

Your Article Summary

See Latest Articles

Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage
Journal of Pharmacology and Experimental Therapeutics, 10/14/09

Tomicic–Christmann M et al. – The data show that p53–deficient/depleted cells are hypersensitive to TPT because they down–regulate XIAP and survivin and thus amplify the intrinsic apoptotic pathway via caspase–3–mediated Bid cleavage. Therefore, in gliomas harboring wild–type p53 TPT–based therapy might be improved by targeted down–regulation of XIAP and survivin.

Related Articles

See all related articles

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
Cancer, 11/06/09    Relevance Score: 80%

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: Pharmacological rationale and clinical response
Pediatric Blood & Cancer, 10/27/09    Relevance Score: 80%

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study d9803
Journal of Clinical Oncology, 10/08/09    Relevance Score: 80%

Today in Basic Science...keeping you current

Receive free subspecialty "5-minute updates" via email

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs
Pharmacology & Therapeutics, 12/16/09

The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways
Trends in Pharmacological Sciences, 12/15/09

UGT1A10: Activity against the tobacco-specific nitrosamine, NNAL, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility
Drug Metabolism and Disposition, 12/14/09

 See all of Basic Science